Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the first patient has been dosed with lead drug candidate RLS-1496 in the company’s single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial. The study marks the first time a GPX4 (glutathione peroxidase) modulator has entered Phase 1 clinical trial and is designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496 in male or female patients 18 years or older with mild to moderate and stable plaque psoriasis. These subjects’ aging skin will also be treated and assessed to see if RLS-1496 can improve biomarkers of aging and reverse the skin age or biological clock. Based on the results of this study, the trial will potentially expand to additional inflammatory skin conditions and autoimmune disorders, including but not limited to atopic dermatitis, vitiligo, rosacea, alopecia areata, and scleroderma.3 A systemic formulation of RLS-1496 is planned to enter Phase 1 clinical trials in 2026.
“We are excited to reach this important milestone not only for our lead candidate RLS-1496 but also for the advancement of longevity science,” said Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, FACMS. “As the first company to treat patients with a GPX4 modulator targeting senescent cells in a data-rich Phase 1 clinical trial, we look forward to assessing its potential disease-altering effects on inflammatory skin conditions and skin aging, driving our pipeline forward in line with our goal of making a meaningful impact on age-related diseases and conditions, such as obesity and pain.”
Rubedo Chief Scientific Officer Marco Quarta, PhD, said, “For the last decade, longevity scientists have been working to develop a compound ready for human trials that safely and effectively targets pathologic senescent cells. We are proud that our team developed RLS-1496 into a topical drug candidate in less than three years from initiation – two times faster than the industry average1 via ALEMBIC™, our proprietary AI-driven drug discovery platform with SenTeCh™ chemistry technology. The other candidates in our pipeline are following similar expedited timelines, including systemic RLS-1496, which is aimed to begin Phase 1 clinical trials in 2026.”
About the RLS-1496 Phase 1 Clinical Trial
The design of the clinical trial is to assess primary and secondary objectives of safety and clinical effects of single and multiple doses of topical RLS-1496, compared to vehicle (control), in patients with mild to moderate stable plaque psoriasis. A key secondary objective is to evaluate the effects of RLS-1496 on target psoriasis lesions using a common measure of psoriasis severity, the modified Investigator’s Global Assessment (mIGA), to evaluate improvement. The trial will be conducted at a single center in The Netherlands with approximately 24 enrolled patients, starting with single dose application followed by a multidose protocol.
The design of the trial was developed with key insights provided by Rubedo’s Clinical Advisory Board (CAB), which is led by Rubedo Chief Medical Officer and dermatologist Mary Spellman, MD. The CAB includes the following leading dermatologists who are both practicing clinicians and researchers, and are supporting Rubedo as strategic and scientific consultants and advisors:
- Mark Lebwohl, MD, Professor & Chairman Emeritus of the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, NY
- Ted Lain, MD, MBA, Executive Director & Principal Investigator, Austin Institute for Clinical Research; CMO, Sanova Dermatology, Austin, TX
- Zoe Draelos, MD, Founder, Dermatology Consulting Services, High Point, NC
- Chris Griffiths, OBE MD FRCP, Emeritus Professor of Dermatology, University of Manchester; Adjunct Professor of Dermatology, Kings College of London, London, England
Dr. Lebwohl said, “As clinicians, we are excited about the potential use of RLS-1496 as a topical treatment for psoriasis, other chronic inflammatory skin conditions, and skin aging itself. As researchers, we are intrigued by RLS-1496 as a potential first-in-class GPX4 modulator that was designed to selectively target inflammaging pathologic senescent cells and surrounding tissues. This is a very important milestone in longevity science, and we are thrilled to be working with the Rubedo team to drive this science forward.”
About RLS-1496 and GPX4 Modulation
Rubedo’s lead candidate RLS-1496 is a potential first-in-class, disease-altering GPX4 modulator selectively targeting pathologic senescent “zombie” cells that drive chronic degenerative diseases and conditions associated with biological aging processes. These include immunology and inflammation (I&I), dermatology and skin aging, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.
GPX4 is a major antioxidant-regulating enzyme that protects cells and tissues from free radical damage and is essential for cell survival. In contrast, GPX4 deficiency is associated with regulated cell death (RCD), especially ferroptosis. In certain pathologic cells, aging is associated with an imbalance in GPX4. By modulating GPX4 to selectively encourage cell death in ferroptosis-sensitive senescent zombie cells, RLS-1496 may be able to clear these cells to not only fight disease, but also support healthy cells to function properly.
About Rubedo Life Sciences
Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.
References
1. https://matchtrial.health/en/how-long-does-it-take-to-develop-a-new-drug/
2. Quarta M, PhD, Co-founder and Chief Scientific Officer, Rubedo Life Sciences. Treatment of ex-vivo biopsies of human skin. Presented at: Advancing Innovation in Dermatology, Dermatology Summit 2025. January 12, San Francisco, CA.
3. Data on file, Rubedo Life Sciences, Sunnyvale, CA 94085.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522955270/en/
Contacts
Investor Contact:
Rubedo Chief Business Officer Ali Siam
alisiam@rubedolife.com
781-974-9559
Media Contact:
Peter Collins
p.collins@togorun.com
908-499-1200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PPG highlights continued progress toward 2030 sustainability targets in latest report22.5.2025 16:31:00 EEST | Press release
PPG (NYSE:PPG) today announced continued progress against its near-term 2030 sustainability targets, including reducing greenhouse gas (GHG) emissions throughout its own operations and value chain, and continued improvement in sustainably advantaged product sales driven by customer demand. “Sustainability is core to our purpose and a key enabler of our enterprise growth strategy,” said Peter Votruba-Drzal, PPG vice president, global sustainability. “It is embedded in how we do business by supporting our customers’ success through sustainably advantaged solutions that deliver industry-leading products, improved performance and operational savings, resulting in reduced water, waste and energy use.” Key highlights in PPG’s 2024 Sustainability Report include: 41% of sales from sustainably advantaged products, such as the PPG ENVIRO-PRIME® EPIC200X solution, which enabled a customer’s facility to reduce CO2 emissions by 3,500 metric tons annually. Significant expansion in renewable energy e
Andersen Consulting Adds Collaborating Firm 2i Solutions22.5.2025 16:30:00 EEST | Press release
Andersen Consulting expands its technology and transformation capabilities through a Collaboration Agreement with 2i Solutions, a technology consulting firm bringing deep ERP and other specialized technological expertise to deliver end-to-end digital transformation solutions to clients. Founded in 2005, 2i Solutions advises clients on enterprise technology transformation, specializing in SAP implementation, support, and customization. With a strong focus on delivering intelligent business solutions, the firm offers services across SAP S/4HANA migration, cloud enablement, data analytics, AI, and enterprise automation. 2i Solutions works with a variety of clients in the utilities, insurance, pharmaceutical, and manufacturing industries, including within the public sector. Their industry-specific solutions and global capabilities allow them to assist companies seeking agility, scalability, and innovation in their IT landscape. “We are excited to collaborate with Andersen Consulting as it
Smartly Adds Reddit to Its AI-Powered Advertising Platform22.5.2025 16:05:00 EEST | Press release
Smartly, the AI-powered advertising technology company recognized as a leader in The Forrester Wave™: Creative Advertising Technologies, today announced the integration of Reddit into its unified platform. This launch enables brands to activate, manage, and measure Reddit campaigns with the same automation, creative intelligence, and cross-channel orchestration that define Smartly’s industry-leading approach. With 108+ million daily active uniques and 100,000+ vibrant communities, Reddit is where over half of online mentions of purchasing decisions are happening (Brandwatch, Global, Oct 2023 - Mar 2024). As the platform scales its flagship shopping solution Dynamic Product Ads, Smartly equips advertisers with the tools to engage Reddit’s intent-driven audiences with precision, agility, and creative relevance. “Our communities thrive on real conversations and shared interests that are naturally commercial, making Reddit a uniquely powerful place for brands to connect with actively engag
Quectel Partners With GEODNET to Deliver RTK Correction Services, Ensuring Centimeter-Level Positioning Accuracy for Mass Market Applications22.5.2025 16:00:00 EEST | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has partnered with GEODNET to deliver Quectel’s Real-Time Kinematic (RTK) Correction Services, enabling high-precision positioning for IoT applications. This partnership allows Quectel to deliver bundled solutions that combine its RTK modules and antennas with GEODNET’s RTK network, setting a new benchmark in the high-precision GNSS market. These solutions are designed to support a wide range of mass-market applications, including consumer robotics, sports, automotive, micro-mobility, precision agriculture and mining. Quectel's RTK Correction Services are built to deliver exceptional accuracy and reliability and designed to deliver centimeter-level positioning accuracy that significantly surpasses the performance of traditional GNSS solutions. The partnership with GEODNET means that Quectel can tailor solutions that are optimized for specific applications, enabling equipment manufacturers to easily navigate around the complex
Saudi Arabia Unveils TOURISE: A Bold Global Platform Set to Redefine and Shape a New Horizon for Tourism at Scale22.5.2025 16:00:00 EEST | Press release
Saudi Arabia’s Minister of Tourism, His Excellency Ahmed Al-Khateeb officially launched TOURISE today, a bold new global platform designed to shape a new horizon and plot a shared roadmap for the next 50 years of tourism. Built for ambition and backed by vision, TOURISE will convene a dynamic cross-section of public and private sector industry giants for the first time. Visionary leaders with tourism, technology, investment, sustainability, and cultural expertise will be connected to tackle critical challenges, unlock transformative opportunities and set the agenda for a sector that is sustainable, equitable and future-focused. Along with global partners from multilateral institutions to private sector leaders, TOURISE is designed to unlock major, unprecedented deal flow, with high-value investment opportunities and access to breakthrough technologies set to be announced and activated through the platform. TOURISE is no ordinary event; it is a global platform structured for year-round
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom